8-K Announcements
6Material company update
Jan 16, 2026·SEC
Material company update
Jan 13, 2026·SEC
Material company update
Dec 12, 2025·SEC
Semler Scientific, Inc.(SMLR)Earnings, Financials & Key Ratios
SMLR•NASDAQ
$20.33
4.0× P/E·Price updated Jun 20, 2026
AboutSemler Scientific, Inc. provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. Its products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. The company offers its products through salespersons and distributors. Semler Scientific, Inc. was incorporated in 2007 and is headquartered in Santa Clara, California.Show more
- Revenue$56M-17.4%
- EBITDA$22M-5.9%
- Net Income$41M+98.7%
- EPS (Diluted)5.13+95.1%
- Gross Margin91.55%+2.0%
- EBITDA Margin38.21%+14.0%
- Operating Margin37.19%+13.9%
- Net Margin72.65%+140.7%
- ROE27.04%-16.3%
SMLR Price & Volume
Semler Scientific, Inc. (SMLR) stock price & volume — 10-year historical chart
Loading chart...
Digital Asset Pivot Obscures Core Revenue Contraction
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Contracting
Profitability:Strained
Financial:Mixed
Cash Flow:Deteriorating
Primary Risk:Treasury asset volatility
Key Thesis Takeaways
- Semler Scientific has undergone a fundamental transformation, shifting from a high-margin medical device provider to a firm heavily exposed to digital asset volatility.
- While the core QuantaFlo platform maintains a robust 91.5% gross margin, the company faces significant headwinds as revenue contracted 44.6% year-over-year in 2025Q3.
- Investors should exercise caution as the firm's reliance on non-operating income and a $539.8 million goodwill balance creates substantial uncertainty regarding long-term valuation and operational sustainability.
Verdict Logic
the company's core revenue has contracted by 44.6% year-over-year, and the decoupling of net income from operating cash flow—which reached -$33.0 million in 2025Q3—suggests unsustainable financial health.
SMLR Growth Metrics
Semler Scientific, Inc. (SMLR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years31.52%
5 Years11.43%
3 Years2.01%
TTM-37.29%
Profit CAGR
10 Years-
5 Years22.08%
3 Years33.42%
TTM203.75%
EPS CAGR
10 Years-
5 Years22.23%
3 Years34.25%
TTM35.52%
Return on Capital
10 Years-5.61%
5 Years41.51%
3 Years27.47%
Last Year13.71%
SMLR Recent Earnings
Semler Scientific, Inc. (SMLR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (91%)●Beat Revenue 8/12 qtrs (80%)
Q1 2026Latest
Feb 17, 2026Metric
Actual
Est
EPS
$3.41+731.5%
$0.54
Rev
—
$3M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$1.07+2575.0%
$0.04
Rev
$7M-9.6%
$8M
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$5.04+5140.0%
$0.10
Rev
$8M+2.8%
$8M
Q2 2025
May 13, 2025Metric
Actual
Est
EPS
$0.76
—
Rev
$9M
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 17, 2026 | $3.41vs $0.54+731.5% | —vs $3M |
| Q4 2025 | Nov 12, 2025 | $1.07vs $0.04+2575.0% | $7Mvs $8M-9.6% |
| Q3 2025 | Aug 4, 2025 | $5.04vs $0.10+5140.0% | $8Mvs $8M+2.8% |
| Q2 2025 | May 13, 2025 | $0.76 | $9M |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Semler Scientific, Inc. (SMLR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $20.33 | $310.75M | 3.96 | -17.44% | 72.65% | 27.04% | — | |
| $0.66 | $22.7M | -1.06 | — | — | -1034.04% | — | |
| $7.41 | $92.58M | -29.64 | 14.52% | -9.05% | -70.95% | — | |
| $1.11 | $7.91M | -2.02 | 47901.74% | -131.27% | -34.42% | — | |
| $9.38 | $1.42B | -9.77 | 24.95% | -21.07% | -443.09% | — | |
| $4.20 | $623.98M | 13.13 | 19.99% | 7.88% | 12.86% | — |
Compare SMLR vs Peers
Semler Scientific, Inc. (SMLR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SMLR SEC Filings & Documents
Semler Scientific, Inc. (SMLR) SEC filings — annual & quarterly reports (10-K, 10-Q)
10-Q Quarterly Reports
1FY 2025
Nov 12, 2025·SEC
Get notified when SMLR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SMLR Frequently Asked Questions
Semler Scientific, Inc. (SMLR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Semler Scientific, Inc.'s revenue?
Semler Scientific, Inc. (SMLR) reported $37.0M in revenue for fiscal year 2024. This represents a 11595% increase from $0.3M in 2011.
How fast is Semler Scientific, Inc. growing?
Semler Scientific, Inc. (SMLR) saw revenue decline by 17.4% over the past year.
Is SMLR profitable?
Yes, Semler Scientific, Inc. (SMLR) is profitable, generating $48.3M in net income for fiscal year 2024 (72.7% net margin).
Dividend & Returns
What is SMLR's return on equity?
Semler Scientific, Inc. (SMLR) has a return on equity (ROE) of 27.0%. This is excellent, indicating efficient use of shareholder capital.
What is Semler Scientific, Inc.'s free cash flow?
Semler Scientific, Inc. (SMLR) had negative free cash flow of $388.7M in fiscal year 2024, likely due to heavy capital investments.